When Numbers Move Stocks – Accenture, Power Metallic and Viromed Medical

Accenture Jumps Over 20%: Is AI Now a Growth Driver?

The market revised its expectations for Accenture upward on Thursday, October 1. The Ireland-based, New York-listed consulting firm rose by as much as 22% during US trading before profit-taking subsequently pushed prices back down. Stronger-than-expected quarterly results and a confident outlook provided the impetus. After months of concerns about the impact of artificial intelligence, a different question now arises: How much additional business will be generated if companies actually integrate AI into their operations?

In the fourth fiscal quarter, Accenture generated revenue equivalent to approximately EUR 16.5 billion. That represented a 6% increase in reporting currency and a 7% increase in local currencies. Revenue exceeded the company’s own forecast range and surpassed analysts’ expectations. All currency conversions are based on the ECB reference rate as of October 1. New order intake reached approximately EUR 19.6 billion, exceeding quarterly revenue. The ratio of new orders to revenue was 1.2.

A key factor for the revaluation is that companies continue to seek external support for digital transformation. AI applications require suitable data, reliable systems, and integration into existing work processes. This can lead to consulting and implementation contracts. At the same time, the same technology can reduce the effort required for individual tasks. Accenture’s economic benefit therefore depends on whether additional projects and more productive work offset potential pressure on prices and billable services.

It is also worth taking a closer look at earnings. Reported quarterly earnings per share rose by 46%. Compared to the adjusted figure from the same quarter last year, the increase is only 9%. The large discrepancy is due to costs associated with business optimization in the same quarter last year. Therefore, anyone who looks only at the highest growth figure overestimates the operational acceleration. For investors, beyond growth, what matters is how much comes from ongoing business and how much from base effects.

For fiscal year 2027, management expects revenue growth of 3 to 6% in local currencies. This range is above analysts’ previous expectations. The jump in the share price thus also shows how cautiously the market had previously viewed the consulting business. Good news can trigger a strong rebound after such a phase. However, it does not automatically mean that all risks have disappeared. Accenture reported lower prices in many areas during the quarter. Customers apparently want to share in the savings generated by more efficient technologies themselves.

The stock’s price pattern has also improved. Trading at around EUR 198.50, the stock is above the moving averages ranging from EUR 148.2 to 173.7. The EUR 195 to 200 range is likely to remain a key resistance zone. Despite the strong recovery, the gap to the highs from early 2025 remains significant. For a lasting trend reversal, new contracts must be executed profitably. The key factor is whether Accenture achieves its growth targets and generates sufficient revenue from the additional business despite price pressure.

Power Metallic Launches Economic Assessment for Nisk

The Canadian explorer Power Metallic Mines is advancing its Nisk project in Québec from a pure exploration initiative toward a preliminary economic assessment (PEA). On October 5, 2026, the company announced that it had engaged BBA Inc. to conduct a preliminary economic assessment for the two deposits, Lion and Nisk Main. The study is intended to examine mining and processing methods, infrastructure requirements, capital and operating costs, and provide an initial assessment of the project’s economic viability. According to the schedule, initial results are expected to be published during the first half of 2027. In an environment where electrification and grid expansion are steadily increasing demand for copper and where governments are seeking secure supply chains for critical raw materials, new copper deposits are becoming increasingly important.

The starting point for the economic assessment is the resource estimate for Lion and Nisk published on September 8. The Lion project area is expected to be the focus of further development. Whether and how Nisk Main will be included in the study also depends on ongoing metallurgical analyses from the drilling program. The initial estimate for Lion reported in September comprises 4.75 million metric tons with an average copper equivalent grade of 3.9%, representing approximately 406 million pounds of contained copper equivalents. More than 85% were classified as an indicated resource. This resource category describes the geological confidence level but is not equivalent to proven, economically mineable reserves. The PEA is now intended to develop more robust assumptions regarding mining, processing, and costs, and to clarify which additional investigations are still necessary for future studies.

However, the new deep drill holes at Lion are already providing another growth driver for the company, though they are not yet included in the resource estimate released on September 8. Drill hole PML-26-125 intersected 5.7 m grading 14% copper equivalent (CuEq) at a vertical depth of just under 800 m. A second drill hole revealed 3.28% CuEq over 7.7 m. According to the company, the mineralization extends more than 25% deeper than the deepest hole in the previous estimate. Assay results are still pending for drill hole PML-26-128, which was drilled to a depth of approximately 900 m. The results could support future resource updates.

In parallel with the technical work, baseline environmental studies and planning for 2027 are already underway. The company has also engaged the Quebec-based consulting firm ethos stratégie to facilitate engagement with local communities and Indigenous groups in the region. Meanwhile, BBA is coordinating the engineering work, while GeoVector and independent experts from SGS are responsible for the project’s geological, resource-related, and metallurgical aspects. According to recent company announcements, the PEA and accompanying environmental, technical, and community engagement programs are to be financed from existing cash reserves. In this way, CEO Terry Lynch’s team is implementing the company’s concrete development step by step, and progress can be observed transparently, tangibly, and verifiably from quarter to quarter.

Viromed Medical Surges: Will the Cold Plasma Study Spark a Turnaround?

A research announcement has once again brought Viromed Medical AG into the spotlight for investors. Last Wednesday evening, the medical technology specialist reported that a study on the application of cold plasma in the lungs had been accepted for publication by a leading scientific journal. The stock rebounded significantly in Xetra trading and was last trading at around EUR 5.80. However, the key economic question stands: When will these scientific advances translate into additional revenue and sustainable earnings?

The study focuses on severe infectious lung diseases, particularly pneumonia associated with mechanical ventilation. According to the company, it demonstrated a significant reduction in pathogens, independent of the specific pathogen, within a defined therapeutic safety window. Tissue examinations reportedly showed no safety-related damage in this area of application. Prof. Dr. Hortense Slevogt serves as the scientific director. Details are expected to be announced following the publication of the scientific article. The announced publication would make the scientific basis more verifiable but does not constitute evidence of completed clinical development.

For Viromed, distinguishing between the products is particularly important. PulmoPlas remains in preclinical development. In contrast, the conformity assessment procedure for ViroCAP med as a Class IIa medical device has been completed; the corresponding certificate was issued in early July, and sales began. A successful study on lung application should therefore not be equated with an already available approval for that application. The path from research data to widespread use may require further evidence and investment.

The half-year figures show that Viromed is still early in this development from a financial perspective. Consolidated revenue rose only slightly, from EUR 2.4 to 2.5 million. At the same time, the net loss increased from EUR 0.8 to 1.1 million. Management cites, among other things, expenses related to the PulmoPlas study as well as for the approval and market launch of ViroCAP med. While these expenditures may lay the groundwork for future business, they initially weigh on earnings. It is therefore crucial how quickly the newly launched sales generate additional revenue and whether the margins on those sales will better cover operating costs in the future.

As of the end of June, Viromed reported EUR 9.5 million in equity and an equity ratio of 67.6%. Financing during the reporting period came primarily from a EUR 2.7 million loan from Perbamed Invest. Future performance will depend on actual financing needs and the pace of commercialization. The longer additional research and sales expenses exceed cash inflows, the more important it becomes to have secure financing options and a clear plan for achieving profitable sales.

The Executive Board expects significantly higher revenue and improved annual earnings for the full year. From a technical analysis perspective, the jump to EUR 5.80 follows a pronounced decline since the summer highs. The share price is above the short-term average of EUR 5.50, while longer-term averages stand at around EUR 6.50 and 6.80. Thus, a sustained trend reversal remains to be seen. The published study details and the next sales figures will be decisive. Only measurable progress in revenue and earnings could translate this renewed attention into a more sustainable valuation.

Accenture surges by about 22% following surprisingly strong quarterly results and a confident outlook, as the market now prices in AI not just as a risk but as a new growth driver for the consulting business. Power Metallic Mines is initiating its transition from a pure exploration project to a mine developer by commissioning a PEA for its Nisk copper project. Viromed Medical is rebounding significantly after a study on the application of cold plasma in the lungs was accepted for publication by a specialized journal, thereby fueling hopes for a turnaround.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.